Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca: Seroquel a key part of company portfolio

AstraZeneca: Seroquel a key part of company portfolio

3rd July 2008

AstraZeneca has reiterated the importance of Seroquel (quetiapine fumarate) following the granting of summary judgement for patent litigation for the drug.

Seroquel is indicated as a treatment for schizophrenia and depressive episodes and acute manic episodes associated with bipolar disorder.

Earlier this week, the US District Court for the District of New Jersey granted AstraZeneca a motion for Summary Judgement of No Inequitable Conduct relating to the compound.

The company had sued Sandoz and Teva Pharmaceuticals after their filing of abbreviated new drug applications with the US Food and Drug Administration to market generic formulations of Seroquel prior to the expiry of its patent in 2011.

As a result of this court decision, the trial originally set to start on August 11th 2008 will now no longer take place as Sandoz and Teva had already conceded the validity of AstraZeneca’s patent and their own infringement of it.

David Brennan, chief executive officer of AstraZeneca, said the company is pleased with the court’s decision to preserve its valid intellectual property.

“Seroquel remains an important part of our company’s portfolio benefiting patients and physicians throughout the world,” he added.

Last month, AstraZeneca submitted Seroquel XR extended release tablets to European regulators using the mutual recognition procedure to gain approval for the compound as a treatment for major depressive disorder including maintenance therapy.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.